30 closest matches · ranked by relevance
Hypertension · Dyslipidemias · Diabetes
Primary: Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c…
Acute Lymphoblastic Leukemia · Brain Tumors
Primary: Brain White Matter Volume for Patients Versus Sibling Controls — 27; 30.3 percentage — p=<.0001
Pediatric Cancer · Quality of Life
Primary: Symptom Screening in Pediatrics Tool (SSPedi) Total Score — 7.9; 11.4 Score on a scale
Cancer
Primary: Differences in Change in Daily Average of Moderate and Vigorous Physical Activity (MVPA) Levels Between Groups — -2.58; -2.12; -7.78 minutes — p=0.90
Health Insurance · Childhood Cancer Survivors
Primary: Acceptability of the Health Insurance Navigation Program — 8.9 units on a scale
Acute Lymphocytic Leukemia
Primary: Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years — 64.9 percentage of participants
Cancer Survivor
Primary: Feasibility as Measured by Study Enrollment Rates, Retention Rates, Adherence to the Intervention, and Reasons for Study Drop Out. — 20; 11; 8; 0 Participants
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
ALL · B Cell Lymphoma · Leukemia
Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…
Other Cancer
Primary: Percentage of Participants Recruited — 20; 20 Participants
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Primary: Average Left-Ventricular Wall Thickness-Dimension Ratio Z-score (LVWT/Dz) — -0.1372; -0.0893; -0.2167; 0.3215 z-score — p=0.15
Hodgkin's Lymphoma
Primary: 3-year Event-Free Survival Probability — 0.887 probability — p=0.9970
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Cancer
Primary: Feasibility of Intervention Measure (FIM) AYA — 4.52 units on a scale
Childhood Embryonal Tumor · Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Germ Cell Tumor
Primary: Event-Free Survival (EFS) — 87.0 Percent probability
Childhood Brain Tumors
Primary: Number of Participants With Objective Response — 1; 5; 6; 18 Participants
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma · Childhood Mixed Cellularity Classical Hodgkin Lymphoma · Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Primary: Event-free Survival — 0.89; 0.87; 0.84; 0.87 Probability of survival
Pediatric Cancer · CNS Tumor, Childhood · Skin Inflammation
Primary: Rate of Cutaneous Reaction — 7 Participants
Neuroblastoma · Medulloblastoma · Brain Tumors
Primary: Determine Feasibility Using Days From the Date of Biopsy to Date of Start of Treatment — 12.2; 19.9; 14.9 Days
Hodgkin Lymphoma
Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival
Osteosarcoma · Medulloblastoma · Sarcoma, Ewing's
Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants
Bone Mineral Density · Bone Strength
Primary: Percent Change in Total Bone Mineral Content (BMC) Per Height Compared Between Intervention and Placebo Groups — 2.72; 3.96 % change in grams/cm — p=0.69
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Protective Titres to PCV13 Serotypes Post-immunization With PCV13+PPV23 — 40; 22 Participants
Cardiovascular Disease · Childhood ALL · Childhood NHL
Primary: Change From Baseline in Brachial Artery Flow-Mediated Dilation at 6-months — -0.5; -3.4 percentage change
Glioblastomas · Sarcoma · Astrocytoma
Primary: Percentage of Eligible Dyads (Parent-child) Who Enroll During a Two-year Period — 100; 100 percentage of dyads
Neuroblastoma · Medulloblastoma · Glioma
Primary: Days to Treatment Will be Used in Order to Determine Feasibility of Using Tumor Samples to Assess Genomic Sequencing Using Predictive Modeling to Make Real-time…
B Precursor Type Acute Leukemia
Primary: Fat Mass — 5.1; 10.7 percent change in fat mass
Childhood Cancer Survivors
Primary: Feasibility Measure: Enrollment (Young Adult Survivors) - Number of Eligible Patients Consented and Completing Baseline — 50; 29 Participants
Lymphoma, Non-Hodgkin · Leukemia, Lymphocytic, B Cell · B-Cell Lymphoma
Primary: Grades of Toxicity by Type of Toxicity — 2; 2; 1; 1 toxicities